ReviewHematology/oncology clinics of North America2011
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Review in Hematology/oncology clinics of North America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- The prognostic role of key factors in renal cell carcinoma with bone metastases.BMC musculoskeletal disorders · 2025Article
- The interplay between the tumor microenvironment and tumor-derived small extracellular vesicles in cancer development and therapeutic response.Cancer biology & therapy · 2024Review
- Macrophage Phenotype in Combination with Tumor Microbiome Composition Predicts RCC Patients' Survival: A Pilot Study.Biomedicines · 2022Article
- LncRNA GAS6 antisense RNA 1 facilitates the tumorigenesis of clear cell renal cell carcinoma by regulating the AMP-activated protein kinase/mTOR signaling pathway.Oncology letters · 2021Article
- Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma.Scientific reports · 2021Article
- Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?Frontiers in oncology · 2020Article
- VHL status regulates transforming growth factor-β signaling pathways in renal cell carcinoma.Oncotarget · 2018Article
- Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.Therapeutic advances in urology · 2015Review
- PD-L1 expression in nonclear-cell renal cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Article
- Renal medullary carcinoma: a case report and brief review of the literature.Ochsner journal · 2014Article
- Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET.PloS one · 2013Article
- Circulating biomarkers in advanced renal cell carcinoma: clinical applications.Current oncology reports · 2012Review
- Treatment selection in metastatic renal cell carcinoma: expert consensus.Nature reviews. Clinical oncology · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Insights into the biology of clear-cell renal cell carcinoma (CCRCC) have identified multiple pathways associated with the pathogenesis and progression of this cancer. This progress has led to the development of multiple agents targeting these pathways, including the tyrosine kinase inhibitors sorafenib, sunitinib, and pazopanib, the monoclonal antibody bevacizumab, and the mTOR inhibitors temsirolimus and everolimus. With the exception of temsirolimus, phase 3 trials tested these agents in patients with clear-cell histology; therefore, their efficacy in non-CCRCC is unclear. To date, there is no established effective therapy for patients with advanced non-CCRCC. This article focuses on treatment options for metastatic non-CCRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.